Adalta EPS
Earnings per Share (EPS) of Adalta (1AD.AX) as of Oct 16, 2026.
Get this data via API
Financial Data API
EPS
-0.00AUD
YoY
-20.52%
Last updated:
Earnings per Share (EPS) of Adalta is 2026 -0.00 AUD. Earnings per Share (EPS) of Adalta was 2025 -0.00 AUD. It decreases by -20.52% higher compared to the previous year.
The Adalta EPS history
3 Years
10 Years
25 Years
Max
EPS
Date
EPS
Jan 1, 2019
-0.18 AUD
Jan 1, 2020
-0.14 AUD
Jan 1, 2021
-0.11 AUD
Jan 1, 2022
-0.10 AUD
Jan 1, 2023
-0.05 AUD
Jan 1, 2024
-0.04 AUD
Jan 1, 2025
-0.00 AUD
Jan 1, 2026
-0.00 AUD
| YEAR | EPS | YoY |
|---|---|---|
| -0.00AUD | -20.52% | |
| -0.00AUD | -93.47% | |
| -0.04AUD | -17.44% | |
| -0.05AUD | -44.63% | |
| -0.10AUD | -14.97% | |
| -0.11AUD | -16.44% | |
| -0.14AUD | -22.57% | |
| -0.18AUD | +4.92% | |
| -0.17AUD | +19.50% | |
| -0.14AUD | +91.32% | |
| -0.07AUD | -50.53% | |
| -0.15AUD | -71.36% | |
| -0.52AUD | +64.25% | |
| -0.31AUD | +7,652.77% | |
| -0.00AUD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Adalta Stock analysis
What does Adalta do? Adalta Ltd is a biotechnology company based in Melbourne, Australia, operating within the Health Care sector. The company focuses on discovering, developing, and commercializing protein-based therapeutics, leveraging its i-body platform technology. Adalta has five active development programs spanning from discovery to Phase II clinical trials, targeting applications in inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic designed for the treatment of fibrotic diseases, including lung fibrosis such as Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD), as well as kidney fibrosis, eye fibrosis, and certain cancers. The company also develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology applications. Additionally, Adalta evaluates several CXCR4 i-bodies. The company went public on August 22, 2016, with its ticker listed as 1AD.AX and ISIN AU0000001AD2. Adalta's website is https://adalta.com.au/. Adalta is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Adalta stock
On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Adalta since 2006 – with annual values, charts, and detailed analysis.
Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.
EPS = Net Income / Shares Outstanding
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Adalta
All Key Metrics — Adalta
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth